Skip to main content
. 2022 Jan 21;12(5):2150–2170. doi: 10.1016/j.apsb.2022.01.012

Table 4.

Anti-sclerostin antibodies approved or in clinical research.

Scl-Ab Phase Treatment Company Ref.
Romosozumab Approval OP Amgen and UCB Inc. 133
Blosozumab II OP Eli Lilly Inc. 125
BPS-804 II OI Mereo BioPharma 71
AMG 167 I Osteopenia Amgen Inc. 133
SHR-1222 I OP Jiangsu Hengrui Medicine Co., Ltd. 134